|
 The final draft guidance from the National Institute for Health and
Care Excellence (NICE) represents a change of tack after the
medicine was rejected last year for treating myelodysplastic
syndromes, which can lead to life-threatening diseases including
leukaemia.
The latest decision follows the submission of revised analyses from
Celgene and further information on the company's proposal to limit
the cost of the drug. Celgene has agreed to provide Revlimid free of
charge for anyone who needs more than 26 monthly cycles of
treatment.
The draft guidance is now open for consultation before NICE issues
final guidance.
(Reporting by Ben Hirschler; Editing by Pravin Char)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
